<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7094090/table_8" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 8</label>
  <title>Target Analysis of Patents on Developing Therapeutic Antibodies for SARS</title>
 </caption>
 <colgroup>
  <col align="left"/>
  <col align="left"/>
  <col align="left"/>
  <col align="left"/>
  <col align="left"/>
 </colgroup>
 <thead>
  <tr>
   <th style="border:none;" align="center" colspan="1" rowspan="1" id="0-0-.">patent number</th>
   <th style="border:none;" align="center" colspan="1" rowspan="1" id="0-1-.">antigen of SARS antibody</th>
   <th style="border:none;" align="center" colspan="1" rowspan="1" id="0-2-.">patent title</th>
   <th style="border:none;" align="center" colspan="1" rowspan="1" id="0-3-.">organization</th>
   <th style="border:none;" align="center" colspan="1" rowspan="1" id="0-4-.">priority date</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td style="border:none;" align="left">EP2112164</td>
   <td style="border:none;" align="left">lipid attachment signals or GPI</td>
   <td style="border:none;" align="left">Antiviral peptides linked to a lipid attachment signals or GPI against enveloped virus such as HIV, avian flu, SARS or Ebola virus</td>
   <td style="border:none;" align="left">Institute Pasteur of Shanghai</td>
   <td style="border:none;" align="left">20080229</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">WO2009128963</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Cross-neutralizing human monoclonal antibodies to SARS-CoV and methods of use thereof</td>
   <td style="border:none;" align="left">Institute for Research In Biomedicine</td>
   <td style="border:none;" align="left">20080117</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">WO2009128963</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Cross-neutralizing human monoclonal antibodies to spike protein of SARS coronavirus and methods of use thereof</td>
   <td style="border:none;" align="left">Humab, LLC</td>
   <td style="border:none;" align="left">20080117</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">WO2008035894</td>
   <td style="border:none;" align="left">viral infection</td>
   <td style="border:none;" align="left">Preparation of antiviral antibody 3D8 fragments and their use in treatment of viral infection</td>
   <td style="border:none;" align="left">Sung Kyun Kwan University; Ajou University; Invitroplant Co., Ltd.</td>
   <td style="border:none;" align="left">20060919</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">WO2008060331</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Antibodies to SARS coronavirus</td>
   <td style="border:none;" align="left">Amgen Inc.</td>
   <td style="border:none;" align="left">20060519</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">WO2007044695</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Neutralizing monoclonal anti-spike protein antibodies for diagnosis and treatment of SARS-coronavirus-associated disease and screening of vaccine or anti-SARS agent</td>
   <td style="border:none;" align="left">Dana-Farber Cancer Institute</td>
   <td style="border:none;" align="left">20051007</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">CN1911963</td>
   <td style="border:none;" align="left">RBD of S protein</td>
   <td style="border:none;" align="left">Method for preparing neutralizing monoclonal antibody against severe acute respiratory syndrome coronavirus and its application</td>
   <td style="border:none;" align="left">Chinese Academy of Sciences</td>
   <td style="border:none;" align="left">20050810</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">CN1903878</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Fab fragment of human antibody IgG against SARS coronavirus</td>
   <td style="border:none;" align="left">Fudan University</td>
   <td style="border:none;" align="left">20050726</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">WO2006095180</td>
   <td style="border:none;" align="left">S2 protein</td>
   <td style="border:none;" align="left">Human monoclonal antibodies against SARS-associated coronavirus and treatment of patients with SARS</td>
   <td style="border:none;" align="left">Ultra Biotech Ltd.; University of California</td>
   <td style="border:none;" align="left">20050310</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">WO2006086561</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus</td>
   <td style="border:none;" align="left">New York Blood Center, Inc.</td>
   <td style="border:none;" align="left">20050208</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">CN1664100</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Preparation of heavy chain and light chain variable regions of anti-SARS coronavirus antigen antibodies and their diagnostic and therapeutic uses thereof</td>
   <td style="border:none;" align="left">Chen Zhinan</td>
   <td style="border:none;" align="left">20050204</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">CN1660912</td>
   <td style="border:none;" align="left">IL-8</td>
   <td style="border:none;" align="left">Sequences of monoclonal antibodies against human interleukin 8 and therapeutic use</td>
   <td style="border:none;" align="left">Ye Qingwei</td>
   <td style="border:none;" align="left">20041208</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">WO2006051091</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Compositions against SARS-coronavirus and uses thereof</td>
   <td style="border:none;" align="left">Crucell Holland BV</td>
   <td style="border:none;" align="left">20041111</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">WO2006051091</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Compositions against SARS-coronavirus comprising at least two immunoglobulins reacting with non-competing epitopes, and therapeutic and diagnostic uses thereof</td>
   <td style="border:none;" align="left">Crucell Holland BV</td>
   <td style="border:none;" align="left">20041111</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">CN1673231</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Monoclonal antibody of SARS coronavirus N protein and its use in treatment of SARS virus infections</td>
   <td style="border:none;" align="left">Chinese Academy of Sciences</td>
   <td style="border:none;" align="left">20040715</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">US20060240551</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus</td>
   <td style="border:none;" align="left">New York Blood Center, Inc.</td>
   <td style="border:none;" align="left">20040602</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">WO2005054469</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Anti-SARS-coronavirus monoclonal antibodies, and diagnostic, therapeutic and vaccine preparation uses</td>
   <td style="border:none;" align="left">Health Canada</td>
   <td style="border:none;" align="left">20031205</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">WO2005060520</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Antibodies specific to SARS-CoV spike protein for diagnosis and therapy of SARS and for screening of epitopic vaccines or anti-SARS therapeutics</td>
   <td style="border:none;" align="left">Dana-Farber Cancer Institute, Inc.</td>
   <td style="border:none;" align="left">20031125</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">US20050106563</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Epitope profiles of SARS coronavirus for use in antigen detection, antibody production, and defense against infection</td>
   <td style="border:none;" align="left">Genesis Biotech Inc.</td>
   <td style="border:none;" align="left">20030908</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">US20050069869</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">SARS coronavirus codon-optimized sequences for spike (S) protein expression, anti-S human monoclonal antibodies, and therapeutic and diagnostic uses thereof</td>
   <td style="border:none;" align="left">University of Massachusetts</td>
   <td style="border:none;" align="left">20030804</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">WO2005012360</td>
   <td style="border:none;" align="left">S and N proteins</td>
   <td style="border:none;" align="left">Antibody binding molecules specific for SARS coronavirus</td>
   <td style="border:none;" align="left">Crucell Holland BV</td>
   <td style="border:none;" align="left">20030722</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">CN1566155</td>
   <td style="border:none;" align="left">S, N, and M proteins</td>
   <td style="border:none;" align="left">Antibody library-derived human monoclonal anti-SARS virus antibodies for treating severe acute respiratory syndrome</td>
   <td style="border:none;" align="left">Igcon Therapeutics Co., Ltd.; Genetastix Corporation</td>
   <td style="border:none;" align="left">20030710</td>
  </tr>
  <tr>
   <td style="border:none;" align="left">WO2005007671</td>
   <td style="border:none;" align="left">spike protein</td>
   <td style="border:none;" align="left">Compositions and methods for treating SARS using peptides derived from SARS virus E2 N-terminal-alpha helix or C-terminal-alpha helix and related monoclonal antibody</td>
   <td style="border:none;" align="left">Epitomics, Inc.</td>
   <td style="border:none;" align="left">20030429</td>
  </tr>
 </tbody>
</table>
